Inhibition of IL-1 or IL-6 has clearly demonstrated to be effective in controlling clinical and laboratory inflammatory manifestations of Still’s disease, with a strong glucocorticoid sparing effect and a tolerable safety profile (21, 24, 25). Here, IL1B is linked to systemic-onset juvenile idiopathic arthritis.